LRP-1 variation is not associated with risk of Alzheimer's disease

International Journal of Molecular Epidemiology and Genetics

Volumn 1, Issue 2, 2010, Pages 104-113

  Chalmers, Katy A ^a   Barker, Rachel ^a   Passmore, Peter A ^b   Panza, Francesco ^c,d   Seripa, Davide ^d   Solfrizzi, Vincenzo ^c   Love, Seth ^a   Prince, Jonathan A ^e   Kehoe, Patrick G ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF BARI   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Association analysis; LRP 1

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77954639746     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Love S, Miners S, Palmer J, Chalmers K and Kehoe P. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Frontiers in Bioscience 2009; 14: 4778-4792.
2. Kehoe PG. Alzheimer's disease, Genetics of John Wiley & Sons, Ltd., Chichester, 2008.
3. Howell S, Nalbantoglu J and Crine P. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 1995; 16: 647-652.
4. Hu J, Igarashi A, Kamata M and Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. Journal of Biological Chemistry 2001; 276: 47863-47868.
5. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ and Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 1550-1552.
6. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y and Saido TC. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000; 6: 143-150.
7. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG and Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathology 2008; 18: 240-252.
8. Weller RO, Massey A, Kuo YM and Roher AE. Cerebral amyloid angiopathy: accumulation of A beta in interstitial fluid drainage pathways in Alzheimer's disease. Annals of the New York Academy of Sciences 2000; 903: 110-117.
9. Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM and Roher AE. Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. American Journal of Pathology 1998; 153: 725-733.
10. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL and Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
11. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ and Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093.
12. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, European Alzheimer's Disease Initiative I, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M and Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099.
13. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J and Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. 2000; 1489-1499.
14. Qiu Z, Strickland DK, Hyman BT and Rebeck GW. Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. 1999 1393-1398
15. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D and Holtzman DM. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285-3290.
16. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE and Zlokovic BV. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43: 333-344.
17. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V and Stopa EG. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol (Berl) 2006; 112: 405-415.
18. Ulery PG, Beers J, Mikhailenko I, Tanzi RE, Rebeck GW, Hyman BT and Strickland DK. Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptorrelated protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. 2000; 7410-7415.
19. Waldron E, Heilig C, Schweitzer A, Nadella N, Jaeger S, Martin AM, Weggen S, Brix K and Pietrzik CU. LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiology of Disease 2008; 31: 188-197.
20. Herz J and Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002; 71: 405-434.
21. Frears ER, Stephens DJ, Walters CE, Davies H and Austen BM. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999; 10: 1699-1705.
22. Hooper NM, Trew AJ, Parkin ET and Turner AJ. The role of proteolysis in Alzheimer's disease. Adv Exp Med Biol 2000; 477: 379-390.
23. Simons K and Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002; 110: 597-603.
24. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG and Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 6460-6464.
25. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, Menold MM, Conneally PM, Small GW, Vance JM, Saunders AM, Roses AD and Haines JL. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. [see comment]. JAMA 1997; 278: 1237-1241.
26. Scott WK, Yamaoka LH, Bass MP, Gaskell PC, Conneally PM, Small GW, Farrer LA, Auerbach SA, Saunders AM, Roses AD, Haines JL and Pericak-Vance MA. No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease. Neurogenetics 1998; 1: 179-183.
27. Wu WS, Holmans P, Wavrant-DeVrieze F, Shears S, Kehoe P, Crook R, Booth J, Williams N, Perez-Tur J, Roehl K, Fenton I, Chartier-Harlin MC, Lovestone S, Williams J, Hutton M, Hardy J, Owen MJ and Goate A. Genetic studies on chromosome 12 in late-onset Alzheimer disease.[see comment]. JAMA 1998; 280: 619-622.
28. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J and Owen MJ. A full genome scan for late onset Alzheimer's disease. Human Molecular Genetics 1999; 8: 237-245.
29. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ and Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997; 49: 56-61.
30. Pritchard A, Harris J, Pritchard CW, St Clair D, Lemmon H, Lambert JC, Chartier-Harlin MC, Hayes A, Thaker U, Iwatsubo T, Mann DM and Lendon C. Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease. Neurosci Lett 2005; 382: 221-226.
31. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G and Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
33. Barrett JC, Fry B, Maller J and Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
34. Hill WG. Estimation of linkage disequilibrium in randomly mating populations. Heredity 1974; 33: 229-239.
35. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T and Frangione B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40(apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993; 293: 27-30.
36. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B and Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 4229-4234.
37. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R and Zlokovic BV. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007; 27: 909-918.
38. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM and Holtzman DM. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004; 41: 193-202.
39. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J and Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489-1499.